Postprogression therapy and confounding for the estimated treatment effect on overall survival in phase III oncology trials
Objective Estimations of the treatment effect on overall survival (OS) may be influenced by post-progression therapies (PPTs). It is unclear how often OS analyses account for PPT effects. The purpose of this cross-sectional analysis was to determine the prevalence of OS analyses accounting for PPT e...
Saved in:
Main Authors: | Pavlos Msaouel, Ramez Kouzy, Joseph Abi Jaoude, Ethan B Ludmir, Alexander D Sherry, Timothy A Lin, Esther J Beck, Avital M Miller, Adina H Passy, Gabrielle S Kupferman, Eugene J Koay, Clifton David Fuller, Charles R Thomas, Zachary R McCaw |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2024-07-01
|
Series: | BMJ Oncology |
Online Access: | https://bmjoncology.bmj.com/content/3/1/e000322.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Methodological Tutorial Series for Epidemiological Studies: Confounder Selection and Sensitivity Analyses to Unmeasured Confounding From Epidemiological and Statistical Perspectives
by: Kosuke Inoue, et al.
Published: (2025-01-01) -
Giant Pheochromocytoma Diagnosis Confounded by Amphetamine Use
by: Shreya Amin, et al.
Published: (2023-01-01) -
A Review of Stem Cell Translation and Potential Confounds by Cancer Stem Cells
by: Bernadette Bibber, et al.
Published: (2013-01-01) -
Methaemoglobinaemia: a potential confounder in COVID-19 respiratory failure
by: Yang Lin Ting, et al.
Published: (2024-03-01) -
Treatment of Advanced Hepatocellular Carcinoma after Failure of Sorafenib Treatment: Subsequent or Additional Treatment Interventions Contribute to Prolonged Survival Postprogression
by: Masaaki Kondo, et al.
Published: (2017-01-01)